drugset / Trial / NCT00391079

Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS

NCT00391079

Phase 3 Completed 339 enrolled GW Pharmaceuticals Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine (placebo that contains no active ingredient) can help the central neuropathic pain patients experience as a result of multiple sclerosis. This type of pain "central neuropathic pain" is described as shooting, stabbing, burning or searing like sensation, which is often worse at night.

Timeline

Start
2006-09
Primary completion
2008-04
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nabiximols Other / unclassified Other

Indications